Results 81 to 90 of about 6,372 (199)

In vitrometabolism of piperaquine is primarily mediated by CYP3A4 [PDF]

Xenobiotica, 2012
Piperaquine (PQ) is part of a first-line treatment regimen for Plasmodium falciparum malaria recommended by the World Health Organization (WHO). We aimed to determine the major metabolic pathway(s) of PQ in vitro. A reliable, validated tandem mass spectrometry method was developed.
Lee, Tina Ming-Na, Huang, Liusheng, Johnson, Marla K, Lizak, Patricia, Kroetz, Deanna, Aweeka, Francesca, Parikh, Sunil   +6 more
openaire   +5 more sources

Small Molecule Kinase Inhibitors with In Vitro β‐Hematin Formation and Plasmodium falciparum Protein Kinase G Inhibitory Activity Identified Using Machine Learning

ChemMedChem, Volume 21, Issue 3, 12 February 2026.
A random forest machine learning model was used in combination with molecular docking to predict activity of small molecule kinase inhibitors against two crucial antimalarial targets, namely hemozoin crystallization and Plasmodium falciparum protein kinase G. Derazantinib shows most promise as a dual inhibitor.
Jessica L. Thibaud, Nicolaas Salomane, Sarah Harries, Kathryn J. Wicht, Lauren B. Coulson, David Kuter, Kelly Chibale, Katherine A. de Villiers   +7 more
wiley   +1 more source

Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda.

PLoS ONE, 2008
BackgroundUganda recently adopted artemether-lumefantrine (AL) as the recommended first-line treatment for uncomplicated malaria. However, AL has several limitations, including a twice-daily dosing regimen, recommendation for administration with fatty ...
Adoke Yeka, Grant Dorsey, Moses R Kamya, Ambrose Talisuna, Myers Lugemwa, John Bosco Rwakimari, Sarah G Staedke, Philip J Rosenthal, Fred Wabwire-Mangen, Hasifa Bukirwa   +9 more
doaj   +1 more source

Population pharmacokinetics of artemether–lumefantrine plus amodiaquine in patients with uncomplicated Plasmodium falciparum malaria

British Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 589-605, February 2026.
Aims Resistance to the artemisinins and the artemisinin‐based combination therapy (ACT) partner drugs has developed in Southeast Asia, and artemisinin resistance has also emerged in eastern Africa. Triple ACTs (triple artemisinin‐based combination therapies, TACT), consisting of two partner drugs with different mechanisms of action and similar ...
Junjie Ding, Richard M. Hoglund, Rob W. van der Pluijm, James J. Callery, Thomas J. Peto, Rupam Tripura, Sukanta Das, Nguyễn Hoàng Châu, Cholrawee Promnarate, Mavuto Mukaka, Lek Dysoley, Caterina Fanello, Marie A. Onyamboko, Anupkumar R. Anvikar, Mayfong Mayxay, Frank Smithuis, Lorenz von Seidlein, Mehul Dhorda, Chanaki Amaratunga, M. Abul Faiz, Ho Dang Trung Nghia, Nicholas J. White, Nicholas P. J. Day, Arjen M. Dondorp, Joel Tarning   +24 more
wiley   +1 more source

Effect of Food on the Pharmacokinetics of Piperaquine and Dihydroartemisinin

Clinical Drug Investigation, 2015
Piperaquine-dihydroartemisinin combination therapy has established efficacy for the treatment of malaria; however, a more comprehensive understanding of the pharmacokinetic properties and factors contributing to inter- and intra-individual variability is critical to optimize clinical use.
Reuter, S., Evans, A., Shakib, S., Lungershausen, Y., Francis, B., Valentini, G., Bacchieri, A., Ubben, D., Pace, S.   +8 more
openaire   +4 more sources

Population pharmacokinetics of amodiaquine and piperaquine in African pregnant women with uncomplicated Plasmodium falciparum infections

CPT: Pharmacometrics & Systems Pharmacology
Artemisinin‐based combination therapy (ACT) is the first‐line recommended treatment for uncomplicated malaria. Pharmacokinetic (PK) properties in pregnant women are often based on small studies and need to be confirmed and validated in larger pregnant ...
Junjie Ding, Richard M. Hoglund, Harry Tagbor, Halidou Tinto, Innocent Valéa, Victor Mwapasa, Linda Kalilani‐Phiri, Jean‐Pierre Van Geertruyden, Michael Nambozi, Modest Mulenga, Sebastian Hachizovu, Raffaella Ravinetto, Umberto D'Alessandro, Joel Tarning   +13 more
doaj   +1 more source

Efficacy and Day 7 Plasma Piperaquine Concentrations in African Children Treated for Uncomplicated Malaria with Dihydroartemisinin-Piperaquine

PLoS ONE, 2014
Una nueva y prometedora terapia combinada a base de artemisinina (TCA) es la dihidroartemisinina-piperaquina (DHA-PQ). Sin embargo, la farmacocinética de la piperaquina y la relación entre los niveles de fármaco y la eficacia clínica no están completamente caracterizadas, particularmente en niños.
Issaka Zongo, Fabrice A. Somé, Serge Somda, Sunil Parikh, Noël Rouamba, Philip J. Rosenthal, Joel Tärning, Niklas Lindegårdh, François Nosten, Jean Bosco Ouédraogo   +9 more
openaire   +5 more sources

Molecular Markers of Antimalarial Drug Resistance in Plasmodium falciparum From Kumasi, Ghana, 2023

Tropical Medicine &International Health, Volume 31, Issue 1, Page 43-48, January 2026.
ABSTRACT Objectives Artemisinin partial resistance has emerged in East Africa and is feared to spread across the continent, potentially compromising artemisinin‐based combination treatment. Molecular markers can serve as early warning signals for the development of specific drug resistance.
Albert Dennis Kegya, Elizabeth Oppong, Eric Darko, Kwame Ayisi Boateng, Richard Odame Phillips, Melina Heinemann, Michael Ramharter, Clement Igiraneza, Jules Minega Ndoli, Frank P. Mockenhaupt, Welmoed van Loon   +10 more
wiley   +1 more source

Prevalence of Plasmodium Species Using Rapid Diagnostic Tests in Cameroon: First‐Year Data From Routine Malaria Surveillance

BioMed Research International, Volume 2026, Issue 1, 2026.
Background Malaria remains a major public health concern in Cameroon. Although Plasmodium falciparum is the predominant parasite, the prevalence of other Plasmodium species remains poorly documented due to the absence of a formal surveillance system.
Raymond Ngomdjum Tabue, Flora Neh, Elvira Evina, Dominique Amougou Bomba, Junior Voundi Voundi, Jean Fosso, Albert Meka Zeh, Yoel A. Klug   +7 more
wiley   +1 more source

Evaluated dose regimens for piperaquine simulations.

, 2017
Evaluated dose regimens for piperaquine simulations.
Michael D. Edstein (1846186), Prabin Dahal (3628118), Lesley Workman (368956), Khin Maung Lwin (171017), Leah Mwai (181144), Richard M. Hoglund (3628115), Nguyen Xuan Thanh (3628109), Nancy C. Sambol (2793025), Sunil Parikh (370188), Jean Bosco Ouedraogo (3628121), Steffen Borrmann (4910), Elizabeth A. Ashley (237173), Francois Nosten (2580787), Nguyen Ngoc Quang (3628112), Philippe J. Guerin (137002), Nicholas J. White (35779), Ric N. Price (35538), Joel Tarning (387123), Christian Nsanzabana (342692), Issaka Zongo (86854), Nicholas P. J. Day (35781), Karen I. Barnes (265208), Aung Pyae Phyo (232872), Rose McGready (17231)   +23 more
core   +1 more source